Mouse anti-Human, mouse PARK8 (LRRK2) Monoclonal Antibody | anti-LRRK2 antibody

PARK8 (LRRK2) Antibody

Cat. Num. AAA9200016

• Gene Names: LRRK2; PARK8; RIPK7; ROCO2; AURA17; DARDARIN
• Reactivity: Human, mouse
• Applications: Western Blot, ELISA
• Purity: Purified Mouse Monoclonal Antibody (Mab)
• Synonyms: PARK8 (LRRK2); Monoclonal Antibody; PARK8 (LRRK2) Antibody; Leucine-rich repeat serine/threonine-protein kinase 2; Dardarin; LRRK2; PARK8; anti-LRRK2 antibody

• Host: Mouse
• Reactivity: Human, mouse
• Clonality: Monoclonal
• Isotype: Mouse IgG1
• Specificity: This PARK8 (LRRK2) antibody was raised in mice using purified His-tagged recombinant protein comprised of the C-terminal 261 residues of LRRK2.
• Purity/Purification: Purified Mouse Monoclonal Antibody (Mab)
• Form/Format: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.
• Sequence Length: 2527

• Applicable Applications for anti-LRRK2 antibody: Western Blot (WB), ELISA (EIA)
• Application Notes: WB~~1:1000
• Function: Serine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, autophagy, and vesicle trafficking
• Cellular Location: Cytoplasmic vesicle. Perikaryon. Golgi apparatus membrane; Peripheral membrane protein. Cell projection, axon. Cell projection, dendrite. Endoplasmic reticulum membrane; Peripheral membrane protein. Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane. Endosome {ECO:0000250|UniProtKB:Q5S006}. Lysosome Mitochondrion outer membrane; Peripheral membrane protein Note=Colocalized with RAB29 along tubular structures emerging from Golgi apparatus (PubMed:23395371). Localizes to endoplasmic reticulum exit sites (ERES), also known as transitional endoplasmic reticulum (tER) (PubMed:25201882).
• Tissue Location: Expressed in pyramidal neurons in all cortical laminae of the visual cortex, in neurons of the substantia nigra pars compacta and caudate putamen (at protein level). Expressed in neutrophils (at protein level) (PubMed:29127255). Expressed in the brain. Expressed throughout the adult brain, but at a lower level than in heart and liver. Also expressed in placenta, lung, skeletal muscle, kidney and pancreas. In the brain, expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas.
• Preparation and Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Western Blot (WB)

(Anti-PARK8 (LRRK2) Antibody at 1:1000 dilution + Mouse brain lysate Lysates/proteins at 20ug per lane. Secondary Goat Anti-mouse IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 286 kDa Blocking/Dilution buffer: 5% NFDM/TBST.)

Related Product Information for anti-LRRK2 antibody

This gene is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane. Mutations in this gene have been associated with Parkinson disease-8.

Product Categories/Family for anti-LRRK2 antibody

Neuroscience

References

Olfactory heterogeneity in LRRK2 related Parkinsonism. Silveira-Moriyama L, et al. Mov Disord, 2010 Sep 3. PMID 20818658.
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Saunders-Pullman R, et al. Mov Disord, 2010 Sep 3. PMID 20818610.
Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease. Yescas P, et al. Neurosci Lett, 2010 Aug 18. PMID 20727385.
Absence of Commonly Reported Leucine-Rich Repeat Kinase 2 Mutations in Eastern Indian Parkinson's Disease Patients. Sanyal J, et al. Genet Test Mol Biomarkers, 2010 Aug 19. PMID 20722494.
Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain). Ruiz-Martínez J, et al. Mov Disord, 2010 Aug 18. PMID 20721916.

NCBI and Uniprot Product Information

• NCBI GI #: 171846278
• NCBI GeneID: 120892
• NCBI Accession #: NP_940980.3
• NCBI GenBank Nucleotide #: NM_198578.3
• UniProt Accession #: Q5S007; Q6ZS50; Q8NCX9; A6NJU2
• NCBI Official Full Name: leucine-rich repeat serine/threonine-protein kinase 2
• NCBI Official Synonym Full Names: leucine-rich repeat kinase 2
• NCBI Official Symbol: LRRK2
• NCBI Official Synonym Symbols: PARK8; RIPK7; ROCO2; AURA17; DARDARIN
• NCBI Protein Information: leucine-rich repeat serine/threonine-protein kinase 2
• UniProt Protein Name: Leucine-rich repeat serine/threonine-protein kinase 2
• Protein Family: Leucine-rich repeat serine/threonine-protein kinase
• UniProt Gene Name: LRRK2
• UniProt Synonym Gene Names: PARK8
• UniProt Entry Name: LRRK2_HUMAN

NCBI Description

This gene is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane. Mutations in this gene have been associated with Parkinson disease-8. [provided by RefSeq, Jul 2008]

Uniprot Description

LRRK2: a large multidomain protein kinase with a TKL-type kinase domain, multiple protein-protein interaction domains and a mitochondrial Rho domain (MIRO). May play a role in the etiology of Parkinson disease. May also have GTPase activity. Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Interacts with PARK2, PRDX3 and TPCN2. Expressed throughout the adult brain, but at a lower level than in heart and liver. Expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas. Defects in LRRK2 are the cause of Parkinson disease type 8 (PARK8). A slowly progressive neurodegenerative disorder characterized by bradykinesia, rigidity, resting tremor, postural instability, neuronal loss in the substantia nigra, and the presence of neurofibrillary MAPT (tau)-positive and Lewy bodies in some patients.

Protein type: Protein kinase, Ser/Thr (non-receptor); Protein kinase, TKL; EC 2.7.11.1; Kinase, protein; TKL group; LRRK family

Chromosomal Location of Human Ortholog: 12q12

Cellular Component: dendrite cytoplasm; Golgi apparatus; extracellular space; neuron projection; synaptic vesicle membrane; mitochondrion; lysosome; endoplasmic reticulum; dendrite; terminal button; perikaryon; trans-Golgi network; inclusion body; cytosol; lipid raft; mitochondrial outer membrane; cell soma; axon; mitochondrial matrix; cytoplasm; mitochondrial membrane; mitochondrial inner membrane; plasma membrane; cytoplasmic vesicle; cell junction; endosome

Molecular Function: GTPase activity; tubulin binding; identical protein binding; clathrin binding; GTP-dependent protein kinase activity; protein homodimerization activity; Rho GTPase binding; GTP binding; actin binding; GTPase activator activity; protein kinase activity; MAP kinase kinase activity; protein serine/threonine kinase activity; protein binding; SNARE binding; protein kinase A binding; syntaxin-1 binding; kinase activity; glycoprotein binding; ATP binding

Biological Process: regulation of synaptic transmission, glutamatergic; activation of MAPKK activity; positive regulation of protein binding; activation of MAPK activity; protein amino acid autophosphorylation; regulation of neuron maturation; determination of adult life span; protein amino acid phosphorylation; positive regulation of MAP kinase activity; tangential migration from the subventricular zone to the olfactory bulb; negative regulation of protein amino acid phosphorylation; regulation of dopamine receptor signaling pathway; small GTPase mediated signal transduction; regulation of mitochondrial depolarization; negative regulation of protein binding; positive regulation of autophagy; neuromuscular junction development; positive regulation of dopamine receptor signaling pathway; olfactory bulb development; peptidyl-threonine phosphorylation; MAPKKK cascade; endocytosis; regulation of locomotion; positive regulation of programmed cell death; regulation of membrane potential; peptidyl-serine phosphorylation; positive regulation of protein ubiquitination; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; intracellular distribution of mitochondria; autophagy; positive regulation of protein amino acid phosphorylation; response to oxidative stress; regulation of excitatory postsynaptic membrane potential; neurite morphogenesis; positive regulation of GTPase activity

Disease: Parkinson Disease 8, Autosomal Dominant